Post-ASH 2022 Multiple Myeloma

17 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in multiple myeloma from ASH 2022

The Post-ASH 2022 Multiple Myeloma Highlights Virtual Workshop took place on 18 January, and featured a series of short presentations on selected abstracts from the 64th ASH Annual Meeting presented by experts with interactive panel discussions after each session.

Newly diagnosed multiple myeloma Bispecific monoclonal antibodies Smoldering multiple myeloma CAR-T therapy Challenging settings in multiple myeloma

Session 1: Newly diagnosed multiple myeloma

Risk stratification in NDMM & genomic determinants of resistance

Francesco Maura Sylvester Comprehensive Cancer Center, Miami, FL, United States

Updates from the UK OPTIMUM/Muk Nine trial

Martin Kaiser The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom

Isa-KRd in patients with HR-NDMM: analysis of the GMMG-CONCEPT trial

Katja Weisel University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Panel discussion

Session 2: Bispecific monoclonal antibodies

Results from MonumenTAL-1: Talquetamab for R/R myeloma

Ajai Chari Mount Sinai Medical Center, New York City, NY, United States

Elranatamab for patients with R/R myeloma

Noopur Raje Massachusetts General Hospital, Boston, MA, United States

Teclistamab + subcutaneous daratumumab & lenalidomide

Emma Searle The Christie NHS Foundation Trust, Manchester, United Kingdom

Updated results from a study of forimtamig

Carmelo Carlo-Stella Humanitas University, Milan, Italy

Panel discussion

Alnuctamab in patients with R/R multiple myeloma

Sandy Wong University of California San Francisco, San Francisco, CA, United States

A study of Abbv-383 as monotherapy in patients with R/R myeloma

Peter Voorhees Levine Cancer Institute, Atrium Health, Charlotte, NC, United States

Fixed-duration cevostamab therapy in patients with R/R myeloma

Alexander Lesokhin Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Panel discussion

Session 3: Smoldering multiple myeloma

Results from the ASCENT trial: Dara-KRd in high-risk smoldering myeloma

Shaji Kumar Mayo Clinic, Rochester, MN, United States

Results from the randomized Phase III ITHACA trial

Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain

CurativE StrAtegy (GEM-CESAR) for high-risk smoldering myeloma

Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain

Panel discussion

Session 4: CAR-T Cell Therapy

Phase I study of CC-95266 in patients with R/R myeloma

Luciano Costa UAB School of Medicine, Birmingham, AL, United States

Results from the first Phase I study of CC-98633 in patients with R/R myeloma

Luciano Costa UAB School of Medicine, Birmingham, AL, United States

Early and sustained uMRD after ide-cel in patients enrolled in the KarMMa trial

Bruno Paiva University of Navarra, Pamplona, Spain

Preliminary results from the CC-92480-MM-001 trial

Paul Richardson Dana-Farber Cancer Institute, Boston, MA, United States

Panel discussion

Session 5: Challenging settings in multiple myeloma

Ultra-sensitive assessment of MRD in peripheral blood of myeloma patients

Laura Notarfranchi University of Parma, Parma, Italy

Clinical impact of NGF vs QIP-MS to assess MRD in NDMM patients

Noemí Puig University Hospital Salamanca, Salamanca, Spain

Panel discussion

The continued success of the post-ASH meetings is in no small part due to the ongoing funding of supporters, allowing unique opportunities for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future meetings and activities, please contact us here.

For the latest updates in myeloma, explore the Multiple Myeloma Channel

Post-ASH 2022 Multiple Myeloma

Post-ASH 2022 Multiple Myeloma

Sign-up for our Newsletter!